NxStage Medical Inc. (NASDAQ:NXTM) shares reached a new 52-week high during trading on Thursday . The company traded as high as $25.58 and last traded at $25.52, with a volume of 456,789 shares changing hands. The stock had previously closed at $25.16.

Several analysts recently weighed in on the company. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a report on Wednesday, July 6th. BTIG Research restated a “buy” rating and set a $29.00 price target on shares of NxStage Medical in a report on Sunday, August 7th. Piper Jaffray Cos. restated an “overweight” rating and set a $21.00 price target on shares of NxStage Medical in a report on Tuesday, May 17th. Canaccord Genuity restated a “buy” rating on shares of NxStage Medical in a report on Wednesday, May 4th. Finally, Jefferies Group increased their price target on NxStage Medical from $24.00 to $27.00 and gave the company a “buy” rating in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $26.43.

The firm’s market cap is $1.64 billion. The firm has a 50 day moving average price of $22.44 and a 200-day moving average price of $18.21.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. The business earned $92.20 million during the quarter, compared to analysts’ expectations of $89.44 million. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.08) earnings per share. Equities research analysts expect that NxStage Medical Inc. will post ($0.12) EPS for the current year.

Several hedge funds have recently modified their holdings of the company. Rhumbline Advisers raised its stake in shares of NxStage Medical by 8.3% in the fourth quarter. Rhumbline Advisers now owns 68,426 shares of the medical device company’s stock worth $1,499,000 after buying an additional 5,240 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of NxStage Medical by 6.5% in the fourth quarter. Wells Fargo & Company MN now owns 1,450,307 shares of the medical device company’s stock worth $31,777,000 after buying an additional 88,286 shares in the last quarter. Morgan Stanley raised its stake in shares of NxStage Medical by 1.3% in the fourth quarter. Morgan Stanley now owns 67,174 shares of the medical device company’s stock worth $1,472,000 after buying an additional 874 shares in the last quarter. Jennison Associates LLC raised its stake in shares of NxStage Medical by 32.9% in the fourth quarter. Jennison Associates LLC now owns 1,395,174 shares of the medical device company’s stock worth $30,568,000 after buying an additional 345,394 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of NxStage Medical by 4.1% in the fourth quarter. New York State Common Retirement Fund now owns 76,493 shares of the medical device company’s stock worth $1,676,000 after buying an additional 3,000 shares in the last quarter.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.